A new study challenges long‑held ideas about anxiety and attention. It finds that when motivated, anxious people can shift ...

SELECT-AXIS 1 (NCT03178487) was a randomised, multicentre, phase 2/3 study that included a 14-week, double-blind, placebo-controlled period 1 followed by a 90-week, open-label extension period 2. The ...

Dye, Cultural Inheritance, Jiangnan Culture Share and Cite: Zhang, L. and Huang, X. (2025) Innovative Research and Practice of “Hand + Art” Intangible Cultural Heritage Study in Jiangnan Cultural ...

Hassan, R. (2025) The Impact of Entrepreneurship Knowledge Transfer on Economic Empowerment among Housewives of the FELDA Second-Generation in Bera, Pahang. Open Journal of Social Sciences, 13, ...

Five years after Kobe Bryant's untimely passing, his 'Mamba Mentality' still provides quite the intriguing study. It has ...

Objectives We aimed to describe population trends in motivation to stop smoking between 2016 and 2021 in Germany. Furthermore, the aim was to estimate to what extent higher ratings on the validated ...

This study evaluates the impact of incorporating mixed reality—including both augmented and virtual reality—into auto-mechanics training for students enrolled in selected public technical ...

Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an ...

These 2 Foods May Help Lower Your Chronic Disease Risk, New Study Says These two beans might have more power than we realized! Lauren Manaker M.S., RDN, LD, CLEC. Fri, June 6, 2025 at 9:39 PM UTC.

Background: Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor. Objective: To evaluate the efficacy and safety of certolizumab pegol versus placebo, plus methotrexate (MTX), in ...

(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma rapid oral abstract session and a presentation by Dr. Xinan Sheng discussing results from a phase 1b/2 study assessing ...

Data from the Phase 2 CLOVER WaM study (NCT02952508), including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2% (95% CI, 0.42 to 0.67), which exceeded the agreed ...